Table 2 Incidence of nivolumab-induced pneumonitis and UIP diagnosis categories
|  | Total, n | Any grade, n (%) | ≥Grade 3, n (%) |
|---|---|---|---|
Total | 188 | 22 (11.7) | 3 (1.6) |
NSCLC | 96 | 14 (14.6) | 2 (2.1) |
HNC / GC | 92 | 8 (8.7) | 1 (1.1) |
No fibrosis, all tumor types | 148 | 8 (5.4) | 0 |
No fibrosis, NSCLC | 70 | 4 (5.7) | 0 |
No fibrosis, HNC/GC | 78 | 4 (5.1) | 0 |
Pre-existing ILD, all tumor types | 40 | 14 (35.0) | 3 (7.5) |
Inconsistent with UIP, all tumor types | 28 | 9 (32.1) | 1 (3.6) |
Possible UIP/UIP, all tumor types | 12 | 5 (41.7) | 2 (16.7) |
Pre-existing ILD, NSCLC | 26 | 10 (38.5) | 2 (7.7) |
Inconsistent with UIP, NSCLC | 17 | 6 (35.3) | 1 (5.9) |
Possible UIP/UIP, NSCLC | 9 | 4 (44.4) | 1 (11.1) |
Pre-existing ILD, HNC/GC | 14 | 4 (28.6) | 1 (7.1) |
Inconsistent with UIP, HNC/GC | 11 | 3 (27.3) | 0 |
Possible UIP / UIP, HNC/GC | 3 | 1 (33.3) | 1 (33.3) a |